anti-IL-23/TL1A therapeutic (Morphic Therapeutic)

N/A

Report date: 2025/06/11 11:02:33
NME

Base Information

Drug Nameanti-IL-23/TL1A therapeutic (Morphic Therapeutic)
Drug Alias Namedual IL-23/TL1A inhibitor (Morphic Therapeutic)anti-IL-23/TL1A therapeutic (Morphic Therapeutic)MORF SMI
ClassificationSmall molecules
Mechanisms of ActionInterleukin-23 inhibitorsTumor necrosis factor superfamily member 15 inhibitorsImmunomodulators
TargetsTumor necrosis factor superfamily member 15Interleukin-23
Therapy Area/IndicationsInflammationImmune System DiseasesCrohn Disease +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMorphic Therapeutic Inc
China Registration ClassN/A

Develop Information

Active CompaniesMorphic Therapeutic Inc
Inactive CompaniesN/A
Active IndicationsInflammationCrohn DiseaseInflammatory Bowel Diseases +[4] 
Inactive IndicationsImmune System Diseases

Other Information

ATC CodeN/A
Related LinksN/A